Search

Arcutis Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

25.03 0.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.72

Max

25.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

26M

15M

Verkäufe

24M

130M

KGV

Branchendurchschnitt

112.636

57.366

EPS

0.11

Gewinnspanne

11.558

Angestellte

354

EBITDA

23M

17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+47.58% upside

Dividenden

By Acuity

Nächstes Ergebnis

27. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-130M

3.1B

Vorheriger Eröffnungskurs

24.31

Vorheriger Schlusskurs

25.03

Nachrichtenstimmung

By Acuity

50%

50%

167 / 340 Ranking in Healthcare

Arcutis Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Aug. 2026, 19:36 UTC

News

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

24. Aug. 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

21. Aug. 2026, 19:56 UTC

Event

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

20. Aug. 2026, 19:51 UTC

News

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

19. Aug. 2026, 19:26 UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

18. Aug. 2026, 19:56 UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

14. Aug. 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13. Aug. 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12. Aug. 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11. Aug. 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10. Aug. 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7. Aug. 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6. Aug. 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5. Aug. 2026, 23:02 UTC

News
Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4. Aug. 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3. Aug. 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31. Juli 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30. Juli 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29. Juli 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28. Juli 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

27. Juli 2026, 16:07 UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

24. Juli 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

21. Juli 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

20. Juli 2026, 20:14 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Peer-Vergleich

Kursveränderung

Arcutis Biotherapeutics Inc Prognose

Kursziel

By TipRanks

47.58% Vorteil

12-Monats-Prognose

Durchschnitt 36.57 USD  47.58%

Hoch 40 USD

Tief 34 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arcutis Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

7

Buy

0

Halten

0

Sell

Stimmung

By Acuity

167 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat